2019
Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation
Renaghan AD, Jaimes EA, Malyszko J, Perazella MA, Sprangers B, Rosner MH. Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation. Clinical Journal Of The American Society Of Nephrology 2019, 15: 289-297. PMID: 31836598, PMCID: PMC7015091, DOI: 10.2215/cjn.08580719.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationStem cell transplantationCell transplantationKidney injuryHepatic sinusoidal obstruction syndromeAcute kidney injurySinusoidal obstruction syndromeCongenital immune deficiencyDevelopment of CKDType of transplantNonmalignant hematologic disordersStem cell transplantLife-saving therapySickle cell diseaseHigh mortality rateAcute dialysisNephrotoxic medicationsNonrelapse mortalityConditioning regimenHost diseaseInfusion syndromeObstruction syndromeThrombotic microangiopathyTransplant recipientsPatient characteristics
2010
Experience with outpatient computed tomographic-guided renal biopsy.
Margaryan A, Perazella MA, Mahnensmith RL, Abu-Alfa AK. Experience with outpatient computed tomographic-guided renal biopsy. Clinical Nephrology 2010, 74: 440-5. PMID: 21084047, DOI: 10.5414/cnp74440.Peer-Reviewed Original ResearchConceptsNative kidney biopsiesKidney biopsyRenal biopsyPost-biopsy observation periodInpatient observation periodObservation periodLow complication rateTime of admissionYale-New Haven Medical CenterDuration of procedureInstances of deathHemoglobin concentration changesDetectable bleedingSerum creatinineComplication rateMean ageRenal sizeAdequate tissueMedical CenterOutpatient unitDiagnostic tissueBiopsyLaboratory dataTransfusionPatients
2004
Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease
Perazella M, Mosenkis A, Berns J. Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease. Seminars In Dialysis 2004, 17: 411-416. PMID: 15461751, DOI: 10.1111/j.0894-0959.2004.17351.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina, UnstableDiabetes Mellitus, Type 2Diabetic NephropathiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHeparin, Low-Molecular-WeightHumansKidney Failure, ChronicMalePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRisk AssessmentTreatment OutcomeConceptsLow molecular weight heparinIIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeEnd-stage renal diseaseMolecular weight heparinWeight heparinKidney diseaseGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsSafety of LMWHLarge prospective trialsMajor clinical trialsCardiac causesCoronary syndromeAppropriate dosingProspective trialRenal diseaseKidney functionAggressive interventionClinical benefitClinical trialsPatientsSignificant impairmentDisease
1998
Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up.
Cruz D, Mahnensmith R, Brickel H, Perazella M. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. Clinical Nephrology 1998, 50: 101-7. PMID: 9725781.Peer-Reviewed Original ResearchConceptsSymptomatic intradialytic hypotensionIntradialytic hypotensionMidodrine therapyHD sessionSafe therapyEnd-stage renal disease patientsStage renal disease patientsAlpha-1 adrenergic agonistMean ultrafiltration volumeSignificant causative roleRenal disease patientsTreatment-related factorsPatient-specific factorsMost therapeutic interventionsKt/VHypotensive symptomsBlood pressureHemodialysis patientsHD patientsDisease patientsSubjective improvementAdverse reactionsFrustrating complicationMean albuminSafe treatment
1995
Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels
Perazella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia M. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. American Journal Of Kidney Diseases 1995, 26: 495-500. PMID: 7645558, DOI: 10.1016/0272-6386(95)90496-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedEnalaprilErythropoietinFemaleHematocritHumansKidney TransplantationMaleMiddle AgedPolycythemiaTreatment OutcomeConceptsRed blood cell massBlood cell massErythropoietin levelsEnalapril therapyPosttransplant erythrocytosisHemoglobin concentrationMU/mLElevated red blood cell massMean reticulocyte countRed blood cell destructionRenal transplant patientsMean pretreatment valuePlasma volume contractionMean levelsMean hemoglobin concentrationBlood cell destructionRed blood cell productionMechanism of actionEnalapril treatmentTransplant patientsMean hematocritPretreatment valuesBlood cell productionReticulocyte countEnzyme inhibitors